00775.HK
CK Life Sciences Int'l., (Holdings) Inc.
HKSE · Healthcare · Biotechnology · HK
HKD 0.59
+0.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.0B | 5.4B | 5.5B | 5.3B | 5.3B |
| Cost of Revenue | 8.6B | 4.6B | 3.8B | 3.7B | 3.6B |
| Gross Profit | 2.4B | 785.4M | 1.7B | 1.6B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 501.8M | 320.6M | 254.1M | 145.9M | 158.5M |
| SG&A Expense | 1.2B | 600.1M | 195.2M | 578.7M | 138.1M |
| General & Admin Expense | — | — | 115.1M | 82.2M | 78.8M |
| Selling & Marketing Expense | — | — | 80.0M | 52.7M | 59.3M |
| Other Expenses | 110.1M | — | 460.2M | — | 1.1B |
| Total Operating Expenses | 1.8B | 920.7M | 909.5M | 724.5M | 1.4B |
| Cost and Expenses | 10.4B | 5.5B | 4.7B | 5.1B | 5.0B |
| Operating Income (EBIT) | 590.0M | (135.3M) | 783.1M | 223.8M | 219.5M |
| Non-Operating | |||||
| Interest Income | 35.7M | 21.2M | 13.9M | 13.2M | 5.8M |
| Interest Expense | 565.0M | 266.9M | 337.2M | 322.4M | 163.1M |
| Net Interest Income | (529.3M) | (245.7M) | (323.3M) | (309.2M) | (157.3M) |
| Other Non-Op Income/Expense | (723.0M) | 117.3M | (874.5M) | (155.3M) | (14.7M) |
| Non-Operating Income (excl Interest) | 709.9M | — | 537.4M | (167.2M) | — |
| EBT (Pre-Tax Income) | (133.1M) | (18.0M) | (91.5M) | 68.6M | 204.9M |
| Income Tax Expense | 231.6M | 170.4M | 35.1M | 51.3M | 72.9M |
| Bottom Line | |||||
| Net Income | (344.7M) | (188.4M) | (126.6M) | 17.3M | 132.0M |
| Earnings from Cont. Ops | (364.6M) | (188.4M) | (126.6M) | 17.3M | 131.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (343.1M) | (186.8M) | (126.6M) | 17.3M | 132.0M |
| Per Share | |||||
| Basic EPS | (HK$0.04) | (HK$0.02) | (HK$0.01) | HK$0.00 | HK$0.01 |
| Diluted EPS | (HK$0.04) | (HK$0.02) | (HK$0.01) | HK$0.00 | HK$0.01 |
| Revenue Per Share | HK$1.15 | HK$0.56 | HK$0.57 | HK$0.55 | HK$0.55 |
| Shares | |||||
| Basic Shares Outstanding | 9.6B | 9.6B | 9.6B | 9.6B | 9.6B |
| Diluted Shares Outstanding | 9.6B | 9.6B | 9.6B | 9.6B | 9.6B |
| Profitability Metrics | |||||
| EBITDA | 85.7M | (49.4M) | 337.3M | 624.8M | 469.5M |
| D&A | 205.6M | 85.9M | 91.7M | 233.7M | 101.6M |
| EBIT | (120.0M) | (135.3M) | 245.7M | 391.0M | 367.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026